SSPN formulations of novel emtricitabine

Status:

Phase:Pre-clinical

Principal Investigator(s):

Objective:Preclinical assessment of LAI semi-solid prodrug nanoparticle (SSPN) formulations of novel emtricitabine (FTC) prodrugs to prevent HIV infection.

Prevention Option(s):PrEP

Study Design:

Arms and Assigned Interventions

DescriptionAnimals received 140 mg/kg FTC equivalent (SSPN 9 or 10) via 2 intramuscular injections vs an untreated control (n= 7-6 per group).

Mode of DeliveryBiojector

ARMs

Start Date

End Date

none

Enrollment:0

Age range: ↔ any

Population:

Stay up-to-date!